Overview

* Alnylam Q2 2025 net product rev grows 64% yr/yr, beating analyst expectations

* Adjusted EPS for Q2 beats consensus, reflecting operational efficiency

* Company raises 2025 guidance for TTR franchise and total net product revenues

Outlook

* Alnylam raises 2025 TTR net revenue guidance to $2.175 bln-$2.275 bln

* Company updates total net product revenue guidance to $2.65 bln-$2.8 bln

* Alnylam expects 2025 revenue growth of 61%-70% vs 2024

* Company reiterates FY guidance for collaboration and royalty revenues

* Initiation of TRITON-CM Phase 3 trial for nucresiran in ATTR-CM contributes to pipeline advancement

Result Drivers

* AMVUTTRA LAUNCH - Strong uptake of AMVUTTRA for ATTR-CM drives 77% growth in TTR revenues

* GLOBAL APPROVALS - Regulatory approvals for AMVUTTRA in EU, Brazil, UK, and Japan support revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net Beat $773.69 $656.80

Product mln mln (25

Revenue Analysts

)

Q2 Beat $0.32 -$0.77

Adjusted (20

EPS Analysts

)

Q2 $95.48

Adjusted mln

Operatin

g income

Q2 Basic -$0.51

EPS

Q2 -$16.20

Operatin mln

g Income

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)